Prices of 44 drugs and 108 formulations have actually come down during the period, Chemicals and Fertiliser Minister Ananth Kumar said in Rajya Sabha.
He refuted suggestions that price of some drugs used to treat tuberculosis, AIDS, diabetes and heart ailments were on the rise following decontrolling of these drugs.
National Pharmaceutical Pricing Authority (NPPA), he said, through a notification in July had capped the maximum retail price of 108 non-scheduled single ingredient drug formulations related to treatment for diabetes and cardiovascular diseases.
"Out of 108 medicines, only two notifications were withdrawn because they were already covered as scheduled medicines. A large number of manufacturers have already implemented the price reduction," he said.
To a question on the price of anti-cancer tablet G
Kumar said according to WHO Global TB Report, 2014, the estimated number of TB patients in India in the year 2013 was 2.6 million.
He informed the House that a total number of HIV/AIDS (PLHIV) registered in active care at Anti-Retroviral Therapy Centres across the country are 10.98 lakh.
"However, it is estimated that there are around 20.88 lakh people infected in India as per HIV estimation of 2011," he said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)